- Home
- NKSH vs CRBU Comparison
NKSH vs CRBU Comparison
Compare NKSH & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- CRBU
- Stock Information
- Founded
- NKSH 1891
- CRBU 2011
- Country
- NKSH United States
- CRBU United States
- Employees
- NKSH N/A
- CRBU N/A
- Industry
- NKSH Major Banks
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- NKSH Finance
- CRBU Health Care
- Exchange
- NKSH Nasdaq
- CRBU Nasdaq
- Market Cap
- NKSH 172.6M
- CRBU 165.8M
- IPO Year
- NKSH N/A
- CRBU 2021
- Fundamental
- Price
- NKSH $31.40
- CRBU $1.78
- Analyst Decision
- NKSH Strong Buy
- CRBU Strong Buy
- Analyst Count
- NKSH 1
- CRBU 3
- Target Price
- NKSH $38.00
- CRBU $6.67
- AVG Volume (30 Days)
- NKSH 9.0K
- CRBU 729.3K
- Earning Date
- NKSH 10-23-2025
- CRBU 11-05-2025
- Dividend Yield
- NKSH 4.89%
- CRBU N/A
- EPS Growth
- NKSH 15.57
- CRBU N/A
- EPS
- NKSH 1.77
- CRBU N/A
- Revenue
- NKSH $49,801,000.00
- CRBU $9,121,000.00
- Revenue This Year
- NKSH $2.95
- CRBU $9.23
- Revenue Next Year
- NKSH $9.97
- CRBU N/A
- P/E Ratio
- NKSH $17.41
- CRBU N/A
- Revenue Growth
- NKSH 16.22
- CRBU N/A
- 52 Week Low
- NKSH $23.75
- CRBU $0.66
- 52 Week High
- NKSH $32.89
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- NKSH 61.11
- CRBU 46.16
- Support Level
- NKSH $29.33
- CRBU $1.72
- Resistance Level
- NKSH $31.47
- CRBU $1.94
- Average True Range (ATR)
- NKSH 0.68
- CRBU 0.11
- MACD
- NKSH -0.08
- CRBU -0.01
- Stochastic Oscillator
- NKSH 83.81
- CRBU 26.53
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.